Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children.
Fiche publication
Date publication
octobre 2022
Journal
Clinical ophthalmology (Auckland, N.Z.)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DORY Anne
Tous les auteurs :
Bourcier T, Dory A, Dormegny L, Alcazar J, Gaucher D, Sauer A
Lien Pubmed
Résumé
Vernal keratoconjunctivitis (VKC) is an inflammatory condition in children that can cause severe eye complications. Treatment is based on corticosteroid therapy during flare-ups, then antihistamines and cyclosporine in calmer periods. The dosage and posology of cyclosporine are subject to debate.
Mots clés
cyclosporine, vernal keratoconjunctivitis
Référence
Clin Ophthalmol. 2022 10 26;16:3589-3596